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 Less than 10 years ago, mutations of 
fi broblast growth factor 23 ( FGF23 ) were 
shown to be responsible for autosomal 
dominant hypophosphatemic rickets. 1 
Ever since, a large body of data has dem-
onstrated that FGF23 is a major actor in 
phosphate metabolism, and this hormone 
has therefore drawn tremendous attention 
from the community of nephrologists. 
However, the interplay among phosphate, 
calcium, parathyroid hormone (PTH), 
vitamin D, and FGF23 in the chronic kid-
ney disease (CKD) context remains not 
fully understood. At physiological con-
centrations, FGF23 signals through FGF 
receptors (FGFRs) 1, 3, and 4 only when 
bound to Klotho, a transmembrane pro-
tein that can also be released from the cell 
surface and that acts as a co-receptor. 
Th us, the expression and / or availability of 
Klotho determine the tissue specifi city 
and, potentially, the amplitude of eff ects 
of its ligand, FGF23. Th e phenotypes of 
 FGF23   −  /  −   and  Klotho   −  /  −   mice are very 
similar (high phosphate and calcitriol 
serum levels and tissue calcifi cations), 
suggesting that many characteristics of 
Klotho defi ciency result from a lack of 
FGF23 action, and constituting further 
evidence that Klotho controls FGF23 sig-
naling. Klotho has a rather restricted pat-
tern of expression: kidney (distal tubules), 
parathyroid glands, brain, muscles, 
gonads, duodenum, and pancreas. Th e 
essential role of FGF23 is to regulate renal 
phosphate handling by enhancing kidney 
proximal tubule phosphate excretion in 
urine through the downregulation of the 
sodium – phosphate cotransporters NPT2a 
and NPT2c. Matrix-embedded osteocytes, 
the most abundant bone cells, account for 
most of the physiological circulating 
FGF23 levels. 2 In bone, FGF23 synthesis 
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is stimulated by calcitriol, and, in turn, as 
a negative-feedback loop, FGF23 reduces 
1,25(OH) 2 vitamin D serum concen-
tration via inhibition of 25-hydroxyvita-
min D – 1  -hydroxylase (CYP27B1) and 
stimu lation of 24-hydroxylase activity 
(CYP24) in kidney tubules ( Figure 1a ). 3 
Interestingly, disruption of the calcitriol 
signaling pathway (through vitamin D 
receptor (VDR) or 25-hydroxyvitamin 
D – 1  -hydroxylase deletion) blunts most 
of the eff ects on mineral metabolism and 
tissue calcifi cations induced by FGF23 or 
Klotho defi ciency. 4,5 
 Th e relationships between FGF23 and 
parathyroid glands remain a matter of 
debate. On the one hand, there is solid 
evidence that FGF23 downregulates PTH 
secretion. Parathyroid cells express both 
FGFR1 and FGFR3, as well as Klotho. 6 
Urakawa  et al. showed that intravenous 
injection of FGF23 in mice or rats rapidly 
induces the expression of  egr1 , an early 
gene downstream of FGFR signaling, in 
parathyroid glands. 7 Moreover, addition 
of FGF23 to rat or bovine parathyroid 
gland cell cultures decreases PTH secre-
tion 6 and mRNA expression 8 in a dose-
dependent manner. Finally, in contrast to 
its eff ects in the kidney, FGF23 stimulates 
25-hydroxyvitamin D – 1  -hydroxylase in 
parathyroid glands, suggesting that it 
could also indirectly downregulate PTH 
expression through an increase in the 
local production of calcitriol. Moreover, 
Klotho may play an FGF23-independent 
role in low-calcium-induced PTH release, 9 
making things even more complicated. 
 On the other hand, there are experi-
mental or clinical conditions in which 
PTH and FGF23 levels can be increased 
concomitantly, which could be explained 
in some, but not all, cases by a disruption 
of the FGF23 signaling pathway. First, 
mice overexpressing FGF23 exhibit high 
PTH serum levels with parathyroid gland 
hyperplasia, which were previously attrib-
uted to the concomitant decrease in serum 
1,25(OH) 2 vitamin D. 
10 Brownstein 
 et al. 11 reported the case of a hypophos-
phatemic patient with both severe 
 hyperparathyroidism and increased 
FGF23 serum levels. Th is patient exhib-
ited high levels of serum Klotho (due 
to a chromosomal translocation with a 
breakpoint adjacent to the  Klotho gene), 
see original articles on pages 211 and 232 (77(3), February 2010) 
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glands with nodular hyperplasia as com-
pared with diffuse hyperplasia, which 
coincided with higher nuclear labeling of 
Ki67, a marker of cell proliferation. Th ese 
data suggest that the expected eff ects of 
high serum FGF23 concentrations on 
PTH secretion could be blunted by a 
decreased sensitivity of hyperplastic para-
thyroid glands to FGF23, through the 
downregulation of its receptor and co-
receptor. Interestingly, Klotho expression 
was shown to be also reduced in the kid-
neys of CKD patients. 16 
 In line with the work of Komaba  et al. 15 
in humans, Galitzer  et al. report a similar 
decrease in both protein and mRNA 
expression of FGFR1 and Klotho in para-
thyroid glands of rats with advanced 
CKD. 17 Moreover, aft er 6 weeks of renal 
failure, FGF23 administration fails to 
reduce PTH serum levels or to induce 
 egr1 parathyroid gland expression  in vivo 
as well as PTH mRNA and protein 
expression  ex vivo . 
 Similar mechanisms of refractory II 
HPT have been previously described. 
Indeed, the decrease in VDR and calcium 
receptor (CaR) expression (more marked 
in the nodular zones) in parathyroid 
glands of uremic rodents and humans 
(also mentioned in the work of Galitzer 
 et al. ,  17 ) was reported earlier, potentially 
explaining the resistance of parathyroid 
glands to calcitriol therapy or high serum 
calcium. 18,19  However, despite a number 
of studies in animal models of CKD, the 
respective role and hierarchy of the loss of 
VDR and CaR, and now of FGFR1, in the 
genesis of refractory secondary hyperpara-
thyroidism and parathyroid gland hyper-
plasia have not been fully unraveled. 
Several issues remain to be addressed in 
order to further understand the patho-
physiological meaning of these fi ndings. 
Is there one common CKD-induced 
mechanism (hyperphosphatemia, for 
instance) that leads to the decline of these 
receptors ’ (and co-receptors ’ ) expression, 
or are they interrelated? When does the 
lowering of FGFR1 and Klotho expression 
occur in humans? In CKD, is it a major 
cause of II HPT or of hyperplasia onset, 
or does it happen secondarily, aft er the 
decrease of VDR and CaR? In the paper 
by Galitzer  et al. , 17 it is shown that FGFR1 
expression declines very early, before the 
 suggesting that Klotho may regulate PTH 
secretion despite high FGF23 levels. In 
addition, Brown  et al. described the case 
of a patient with Jansen ’ s disease — which 
is related to a constitutively activated 
PTH / PTH-related protein receptor and 
thus mimics the features of primary 
hyperparathyroidism — who had elevated 
serum levels of FGF23. Th ese data suggest 
that constitutive activation of the PTH /
 PTH-related protein signaling pathway 
may have, directly or indirectly, a stimula-
tory eff ect on bone-cell FGF23 release, 12 
despite hypophosphatemia. Second, in 
chronic renal failure, the progres sive 
 elevation of serum phosphate induces a 
 progressive increase in FGF23 release as 
glomerular fi ltration declines, result ing in 
very high serum levels in CKD5d patients. 
Elevated FGF23 contributes to the reduc-
tion of serum calcitriol and therefore 
plays a role in the development of secondary 
hyperparathyroidism (II HPT), 13 actually 
predicting its severity 14 ( Figure 1b ). 
 In a recent issue of  Kidney International , 
Komaba  et al. , 15 using immunohisto-
chemistry, showed that expression of both 
FGFR1 and Klotho proteins was reduced 
in hyperplastic parathyroid glands from 
25 CKD5d patients as compared with fi ve 
normal parathyroid tissues. Klotho and 
















































 Figure 1  |  Regulation and effects of FGF23 on phosphate metabolism.  Regulation and 
metabolic effects of FGF23 on phosphate (PO 4 ) metabolism in subjects with normal renal function 
( a ) and in patients with chronic kidney disease on dialysis ( b ). The increase in size of FGF23 and 
parathyroid hormone (PTH) symbols illustrates the elevation of their serum levels. The decrease 
in size of FGF receptor (FGFR), vitamin D receptor (VDR), and calcium receptor (CaR) symbols 
reflects the reduction of protein expression. Thick arrows denote a strong effect; dotted lines 
mean an attenuated pathway. In ( b ): note enlarged parathyroid glands and decreased kidney 
mass. Question marks illustrate some of the remaining questions: potential effect of PTH on FGF23 
release; potential receptor for PTH fragments. The decrease in Klotho and FGFR1 expression in 
parathyroid glands blunts the negative effects of FGF23 on PTH secretion. 1,25(OH) 2 D, 1,25(OH) 2  
vitamin D; R, receptor; PTHrP, PTH-related protein. 
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onset of parathyroid-cell proliferation and 
reduction of VDR and CaR content, 
whereas Klotho expression, aft er an early 
transient increase, drops down at the later 
stage. Th ese data suggest, fi rst, a predom-
inant role of the downregulation of the 
FGF23 signaling pathway in the genesis 
of uremic parathyroid gland disorders, 
and second, that there might be, at the 
early stages of CKD, an upregulation of 
Klotho in order to compensate for the 
progressive loss of FGFR1. It was shown 
that both calcitriol and calcimimetics are 
able to increase VDR and CaR expression 
 in vitro and in uremic rat models of II 
HPT. 20 – 23 How do current therapies aff ect 
FGFR1 and Klotho expression in parath-
yroid glands, given that in the work of 
Komaba  et al. , 15 43 % of patients had 
received  cinacalcet treatment before sur-
gery? Are members of the antidiabetes 
glitazone family, agonists of PPAR  , a fac-
tor that stimulates Klotho transcription, 24 
potentially useful in the treatment of II 
HPT by restoring Klotho expression in 
parathyroid glands? Further use of animal 
models of renal insuffi  ciency – induced II 
HPT, as in the work of Galitzer  et al. , 17 
will help us to better understand the 
observations of Komaba  et al. 15 and the 
kinetics of these disorders; meanwhile, 
data obtained from human parathyroid 
glands, especially with nodular hyperpla-
sia, remain necessary, since the nodular 
feature of this disorder cannot be fully 
mimicked in animals. 25 
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